BioCardia, Inc. (NASDAQ:BCDA – Free Report) – Stock analysts at HC Wainwright reduced their Q2 2026 EPS estimates for BioCardia in a research report issued on Tuesday, June 9th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.19) per share for the quarter, down from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for BioCardia’s Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.42) EPS.
BioCardia (NASDAQ:BCDA – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04).
Check Out Our Latest Analysis on BioCardia
BioCardia Trading Down 5.8%
Shares of BCDA stock opened at $0.81 on Thursday. The firm has a fifty day moving average price of $1.07 and a 200 day moving average price of $1.21. The company has a market cap of $9.22 million, a P/E ratio of -0.89 and a beta of 0.51. BioCardia has a 12 month low of $0.81 and a 12 month high of $2.45.
Hedge Funds Weigh In On BioCardia
Large investors have recently bought and sold shares of the stock. Cetera Investment Advisers acquired a new position in BioCardia in the second quarter valued at $40,000. Geode Capital Management LLC boosted its stake in BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in BioCardia in the fourth quarter valued at $72,000. Institutional investors and hedge funds own 20.57% of the company’s stock.
BioCardia Company Profile
BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.
The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.
Featured Articles
- Five stocks we like better than BioCardia
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
